Pierre Triozzi

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. pmc The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon
    Pierre L Triozzi
    Taussig Cancer Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Transl Med 10:241. 2012
  2. doi request reprint Elevated blood β-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma
    Pierre L Triozzi
    Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Melanoma Res 23:1-7. 2013
  3. doi request reprint Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor
    Pierre L Triozzi
    Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    J Immunother 35:587-94. 2012
  4. doi request reprint Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice
    Pierre L Triozzi
    Taussig Cancer Institute, R40, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cancer Immunol Immunother 61:1441-50. 2012
  5. doi request reprint Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists
    P L Triozzi
    Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Cancer Gene Ther 18:850-8. 2011
  6. doi request reprint Blood biomarkers for uveal melanoma
    Pierre L Triozzi
    Taussig Cancer Center, Cleveland, OH, USA
    Future Oncol 8:205-15. 2012
  7. pmc Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma
    Pierre L Triozzi
    Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Invest Ophthalmol Vis Sci 52:5529-35. 2011
  8. doi request reprint Re-inventing intratumoral immunotherapy for melanoma
    Pierre L Triozzi
    Melanoma Program, The Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
    Immunotherapy 3:653-71. 2011
  9. doi request reprint VB-111 for cancer
    Pierre L Triozzi
    Taussig Cancer Institute, Cleveland, OH 44195, USA
    Expert Opin Biol Ther 11:1669-76. 2011
  10. doi request reprint Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists
    Pierre L Triozzi
    Taussig Cancer Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Vaccine 28:7837-43. 2010

Research Grants

  1. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre Triozzi; Fiscal Year: 2007
  2. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre Triozzi; Fiscal Year: 2009
  3. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre L Triozzi; Fiscal Year: 2010
  4. Uveal Melanoma Micrometastasis
    Pierre L Triozzi; Fiscal Year: 2010

Collaborators

Detail Information

Publications31

  1. pmc The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon
    Pierre L Triozzi
    Taussig Cancer Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Transl Med 10:241. 2012
    ..The association of blood levels of microRNAs (miRs) implicated in angiogenesis with circulating endothelial cells (CEC) and with angiogenic proteins was examined in patients administered drugs with anti-angiogenic activity...
  2. doi request reprint Elevated blood β-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma
    Pierre L Triozzi
    Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Melanoma Res 23:1-7. 2013
    ..In conclusion, measurement of blood levels of β2M in patients with primary uveal melanoma may have prognostic value and may help guide surveillance and adjuvant therapy recommendations...
  3. doi request reprint Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor
    Pierre L Triozzi
    Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    J Immunother 35:587-94. 2012
    ..Serum levels of miRs are potentially useful biomarkers of these effects...
  4. doi request reprint Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice
    Pierre L Triozzi
    Taussig Cancer Institute, R40, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cancer Immunol Immunother 61:1441-50. 2012
    ..Effects on host immune effector and suppressor responses have not been well characterized...
  5. doi request reprint Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists
    P L Triozzi
    Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Cancer Gene Ther 18:850-8. 2011
    ..In CEA-Tg mice, tumor growth can be promoted with rAAV-CEA and TLR agonists. Dendritic and myeloid cells play a regulatory role...
  6. doi request reprint Blood biomarkers for uveal melanoma
    Pierre L Triozzi
    Taussig Cancer Center, Cleveland, OH, USA
    Future Oncol 8:205-15. 2012
    ..The stage is set to translate the advances made in understanding the molecular characteristics of uveal melanoma in order to identify and test clinically useful blood biomarkers of tumor dissemination and/or progression...
  7. pmc Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma
    Pierre L Triozzi
    Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Invest Ophthalmol Vis Sci 52:5529-35. 2011
    ....
  8. doi request reprint Re-inventing intratumoral immunotherapy for melanoma
    Pierre L Triozzi
    Melanoma Program, The Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
    Immunotherapy 3:653-71. 2011
    ..More rigorous clinical testing and improved understanding and modulation of regulatory immune responses are necessary...
  9. doi request reprint VB-111 for cancer
    Pierre L Triozzi
    Taussig Cancer Institute, Cleveland, OH 44195, USA
    Expert Opin Biol Ther 11:1669-76. 2011
    ..VB-111 is a vascular-targeting agent consisting of a non-replicating adenovirus vector with a pre-proendothelin-1 promoter that encodes an apoptotic receptor...
  10. doi request reprint Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists
    Pierre L Triozzi
    Taussig Cancer Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Vaccine 28:7837-43. 2010
    ..Suppressor mechanisms, including those mediated by myeloid cells, may negatively regulate the antitumor immune response...
  11. ncbi request reprint Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma
    Pierre L Triozzi
    Cleveland Clinic Taussig Cancer Institute, R40, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Anticancer Res 30:345-54. 2010
    ..IL-1, however, has also been shown to inhibit tumor progression by promoting antitumor immune responses and by enhancing the activity of chemotherapy...
  12. doi request reprint Targeted therapy for uveal melanoma
    Pierre L Triozzi
    Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, United States
    Cancer Treat Rev 34:247-58. 2008
    ..Clinical trials of some of these approaches have been initiated in patients with metastatic uveal melanoma as well as in the adjuvant setting after primary therapy...
  13. doi request reprint Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo
    Pierre L Triozzi
    Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio USA
    Melanoma Res 18:420-30. 2008
    ..The antitumor effects of imatinib mesylate can vary in vivo when compared with in vitro. Imatinib mesylate can both positively and negatively modify host-tumor interactions in uveal melanoma...
  14. pmc Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
    Oscar Alcazar
    Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
    Int J Cancer 131:18-29. 2012
    ..Modification of decitabine dose, schedule and formulation for differentiation rather than cytotoxic objectives inhibits the growth of melanoma cells in vitro and in vivo...
  15. pmc Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects
    Taolin Yi
    Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH, USA
    Oncotarget 2:1155-64. 2011
    ..Phase II investigations of SSG could safely utilize doses of up to 1200 mg/m2 of SSG for up to 10d alone or in combination with IFN-α2b with or without chemotherapy...
  16. doi request reprint Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial
    Jorge A Garcia
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Glickman Urological and Kidney Institute, Cleveland, OH, USA
    BJU Int 107:562-70. 2011
    ..To determine the clinical and immunomodulatory effects of this combination, a prospective, phase II trial of bevacizumab plus low-dose IL-2 was conducted...
  17. pmc Noncytotoxic differentiation treatment of renal cell cancer
    Soledad Negrotto
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Cancer Res 71:1431-41. 2011
    ..The distinctive mechanism of action of a dose and schedule of DAC designed for noncytotoxic depletion of DNMT1 suggests a potential role in treating RCC...
  18. doi request reprint Circulating tumor cells in uveal melanoma
    Virginia Torres
    Taussig Cancer Institute, Cleveland Clinic Foundation, Ohio, USA
    Future Oncol 7:101-9. 2011
    ..However, more research on the biology of uveal melanoma as well as improvements upon the current technologies are needed...
  19. doi request reprint Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining
    Anita Schwandt
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    J Clin Immunol 31:690-8. 2011
    ..A phase II trial of celecoxib and IFN-α in a targeted population of metastatic renal cell carcinoma patients with maximal COX-2 expression was conducted...
  20. doi request reprint Monosomy 3 by FISH in uveal melanoma: variability in techniques and results
    Mary Aronow
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Surv Ophthalmol 57:463-73. 2012
    ..FISH is a widely available, versatile technology, and when performed optimally has the potential to be a valuable tool for determining the prognosis of uveal melanoma...
  21. pmc p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies
    Yogen Saunthararajah
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Semin Oncol 39:97-108. 2012
    ..Decitabine or 5-azacytidine dose and schedule can be rationalized to emphasize this mechanism of action, as an alternative or complement to conventional apoptosis-based oncotherapy...
  22. doi request reprint Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): Results from a phase I-II clinical trial
    Jorge A Garcia
    Department of Solid Tumor Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH Department of Biostatistics, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH Electronic address
    Urol Oncol 32:33.e11-7. 2014
    ..In an effort to further evaluate the clinical and immune activity of GM-CSF and lenalidomide, we conducted a phase I-II trial in patients with CRPC...
  23. doi request reprint Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma
    Jorge A Garcia
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Clin Cancer Res 14:3052-9. 2008
    ..This study assessed the biological effects and safety of GM-CSF and thalidomide in patients with localized prostate cancer before radical prostatectomy...
  24. pmc A phase I study of sunitinib plus bevacizumab in advanced solid tumors
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Clin Cancer Res 15:6277-83. 2009
    ..The safety and maximum tolerated dose of sunitinib plus bevacizumab was assessed in this phase I trial...
  25. pmc Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial
    Ernest C Borden
    Center for Hematology and Oncology Molecular Therapeutics, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Interferon Cytokine Res 31:433-40. 2011
    ..Continued improvements in understanding of antitumor mechanisms will enhance usefulness of IFNs for nodal or distant metastases from melanoma...
  26. ncbi request reprint Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma
    Pierre L Triozzi
    University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294, USA
    Hum Gene Ther 16:91-100. 2005
    ..The intratumoral injection of ALVAC-IL-12 at these dose levels and according to this schedule was well tolerated and resulted in measurable biologic response in patients with metastatic melanoma...
  27. ncbi request reprint Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma
    Pierre L Triozzi
    The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama 35294 3300, USA
    Clin Cancer Res 11:4168-75. 2005
    ..This response included the production of factors that may suppress the antitumor immunologic activity of these vectors...
  28. ncbi request reprint Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse
    Pierre L Triozzi
    University of Alabama at Birmingham Comprehensive Cancer Center, Alabama 35294 3300, USA
    J Immunother 28:382-8. 2005
    ..This study underscores species differences in the ability to respond to plasmid immunogens...
  29. ncbi request reprint Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity
    Pierre L Triozzi
    Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294 3300, USA
    Cancer Biother Radiopharm 21:553-60. 2006
    ..Because GD3 is expressed also on a subpopulation of human lymphocytes, we characterized the in vitro immune effects of murine R24 and a chimeric anti-GD3 antibody (KW-2871)...
  30. ncbi request reprint A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma
    Andres Forero
    Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294 3300, USA
    Cancer Biother Radiopharm 21:561-8. 2006
    ..KW-2871 (IgG1 kappa chimeric antibody) targets GD3, which is upregulated in melanomas. We conducted a phase I trial of KW-2871 in patients with metastatic melanoma...
  31. ncbi request reprint Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma
    Pierre L Triozzi
    University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294 3300, USA
    Int J Cancer 113:406-14. 2005
    ..The results also suggest potential limitations to the intratumoral administration of cytokines, such as GM-CSF, in mesothelioma...

Research Grants7

  1. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre Triozzi; Fiscal Year: 2007
    ....
  2. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre Triozzi; Fiscal Year: 2009
    ....
  3. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre L Triozzi; Fiscal Year: 2010
    ....
  4. Uveal Melanoma Micrometastasis
    Pierre L Triozzi; Fiscal Year: 2010
    ..Micrometastases, microscopic deposits of tumor that have spread via the bloodstream, are present in many patients with uveal melanoma at diagnosis. This project will test new methods of identifying and inhibiting these deposits. ..